GLP-1 analogs are able to directly affect not only other important cardiovascular risk factors, including high blood pressure, dyslipidemia, or obesity, but also the hyperglycemia in diabetic patients. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.